{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:59Z","timestamp":1761870839345,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clml.2016.03.007","type":"journal-article","created":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T04:36:55Z","timestamp":1459831015000},"page":"S101-S104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Adherence to Monitoring Tests in Patients With Chronic Myeloid Leukemia in Lebanon"],"prefix":"10.1016","volume":"16","author":[{"given":"Marcel","family":"Massoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riwa","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Hawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouad","family":"Kerbage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.03.007_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL\u2013positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2016.03.007_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.03.007_bib3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.03.007_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.03.007_bib5","first-page":"e2014009","article-title":"Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)","volume":"6","author":"Ibrahim","year":"2014","journal-title":"Hematol Infect Dis"},{"key":"10.1016\/j.clml.2016.03.007_bib6","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.03.007_bib7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.03.007_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0609.2004.00287.x","article-title":"Assessment of the response to imatinib in chronic myeloid leukemia patients: comparison between the FISH, multiplex, and RT-PCR methods","volume":"73","author":"Raanani","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.03.007_bib9","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.03.007_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.03.007_bib11","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.03.007_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.critrevonc.2010.07.003","article-title":"The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era","volume":"79","author":"Breccia","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2016.03.007_bib13","first-page":"3770","article-title":"Pharmacologic monitoring of dasatinib as first line therapy in newly diagnosed chronic phase chronic myelogenous leukemia (CPCML) identifies patients at higher risk of pleural effusion: a sub-analysis of the OPTIM-Dasatinib Trial","volume":"120","author":"Rousselot","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2016.03.007_bib14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","article-title":"How I treat newly diagnosed chronic phase CML","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.03.007_bib15","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1517\/14656566.2013.833185","article-title":"Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations","volume":"14","author":"Haznedaroglu","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2016.03.007_bib16","first-page":"1673","article-title":"Second-generation BCRABL kinase inhibitors in CML","volume":"363","author":"Beyazit","year":"2010","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016300192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016300192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:47Z","timestamp":1761870467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016300192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":16,"alternative-id":["S2152265016300192"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.03.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to Monitoring Tests in Patients With Chronic Myeloid Leukemia in Lebanon","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}